Vicki R Davis

US Patent:

20130072539, Mar 21, 2013

Filed:

Oct 12, 2010

Appl. No.:

13/497954

Inventors:

Vicki L. Davis - Seven Fields PA, US
David Lapinsky - Allison Park PA, US

International Classification:

C07D 209/20
A61P 35/00
A61K 31/4045

US Classification:

514415, 548507

Abstract:

A particularly constructed tamoxifen-melatonin hybrid ligand gives new and unexpectedly improved results in the prevention and treatment of cancer, particularly breast cancer. The hybrid ligand comprises either tamoxifen or 4-hydroxy-tamoxifen and also melatonin, with the tamoxifen or 5-hydroxy-tamoxifen and melatonin's being linked by an unsubstituted C-Calkyl liner between the tamoxifen amine and the carbonyl of melatonin.

US Patent:

20140171396, Jun 19, 2014

Filed:

Dec 10, 2013

Appl. No.:

14/101453

Inventors:

- Pittsburgh PA, US
Vicki L. Davis - Seven Fields PA, US

Assignee:

Duquesne University of the Holy Spirit - Pittsburgh PA

International Classification:

A61K 31/57
A61K 31/4045
A61K 31/567

US Classification:

514170

Abstract:

A combination hormone and melatonin therapy is provided to reduce the risk of developing, or to reduce the severity of, breast cancer by administering at least one estrogen hormone and optionally at least one progesterone-receptor-binding compound or composition and melatonin together, preferably at normal bed time.